The P.R.I.T.® lung model to test nanoparticle-based drugs

The German technology P.R.I.T.® with its air-liquid interface imitates lung behaviour. It is used for the first time to test a nanoparticle-based drug designed for inhalation.

Many studies require scientists to investigate effects of inhaled substances in lungs. One can think of studies related to smoking behaviors or urban pollution effects. Such studies are also needed for some drug development processes.  For example, the PneumoNP project develops a drug made for inhalation. Toxicity is tested also by investigating lung reactions under drug exposure.

There are several ways to forecast reaction of lungs to a substance without exposing humans. For example, animal models are used for clinical trials. Of course, ethical considerations encourage alternative methods to limit such in vivo tests. The Fraunhofer ITEM Institute in Hannover, Germany, developed an “in vitro model of lungs”. In 2017 and for the first time, this system, called P.R.I.T.®, will be used for testing nanoparticle-based drugs.

The P.R.I.T.® system belongs to the family of air-liquid interface setups. Basically, lung cells are placed on a membrane at the interface between the inhaled atmosphere and the culture medium that acts as blood input. These samples are exposed to a controlled test atmosphere containing the drug. Many parameters can be specifically defined like the composition of the air, the flow or even pressure. The great advantage of this technique is the almost-accurate replication of real-life lungs.

P.R.I.T.® air-liquid interface system principle and setup for the PneumoNP project

P.R.I.T.® air-liquid interface system principle and setup for the PneumoNP project

For the PneumoNP project, a nebulizer has been connected to the P.R.I.T.® system to test a drug made for inhalation. Scientists place human cells in the exposure unit and inject the nebulized drug in the air flow. The study aims to check the toxicity of the therapeutic formulation. Scientists are currently focussing on effects of the drug on lung cells and their genes. Using the P.R.I.T.® technology to test a nanoparticle-based drug is a premiere.

The Fraunhofer ITEM Institute is currently leading the study in their laboratory based in Hannover. First results will be publicly released by the end of the year. Beside the PneumoNP study, they use the P.R.I.T.® system within other projects for testing aerosols, particles and volatile organic compounds (VOCs).



Read more PneumoNP news


Join the Molecular Imaging Workshop 2017

The second edition of the Molecular Imaging Workshop 2017 (MIW2017) will be held from 20th to 23rd November 2017 in San Sebastian, ...
Read More
ETP Nanomedicine is the European Forum aiming at developping, supporting and promoting the field of nanotechnologies applied to medicine.
ETP Nanomedicine translates business, clinical interface, toxicology and characterisation, education and training, ethics and social impact to pursue its goal. Indeed, the organisation intent is to enable diagnostics and imaging, therapy and targeted delivery, and regenerative medicine.

Meet us at the ETPN2017 event

PneumoNP partners will attend the ETPNanomedicine event in Malaga, Spain from 17th to 19th October 2017. The European Technology Platform on ...
Read More
FIGON Conference

Meet us at the FIGON Dutch Medicine Days

PneumoNP partners will attend FIGON Dutch Medicine Days in Ede, the Netherlands on 2nd and 3rd of October 2017. ...
Read More